{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:58:48Z","timestamp":1773316728249,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Cholecystokinin 2 receptor (CCK<jats:sub>2<\/jats:sub>R) is a promising target for imaging and treatment of medullary thyroid cancer due to its overexpression in over 90% of tumor cells. <jats:sup>68<\/jats:sup>Ga-DOTA-CCK-66 is a recently introduced PET tracer selective for CCK<jats:sub>2<\/jats:sub>R, which has shown favorable pharmacokinetics in vivo in preclinical experiments. In order to further investigate safety and suitability of this tracer in the human setting, whole-body distribution and radiation dosimetry were evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Six patients with a history of medullary thyroid cancer were injected intravenously with 169 \u00b1 19 MBq of <jats:sup>68<\/jats:sup>Ga-DOTA-CCK-66. Whole-body PET\/CT scans were acquired at 10 minutes, 1 hour, 2 hours, and 4 hours after tracer injection. Time-activity curves per organ were determined, and mean organ-absorbed doses and effective doses were calculated using OLINDA\/EXM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Injection of a standard activity of 150 MBq of <jats:sup>68<\/jats:sup>Ga-DOTA-CCK-66 results in an effective dose of 4.5 \u00b1 0.9 mSv. The highest absorbed organ doses were observed in the urinary bladder wall (40 mGy) and the stomach (15 mGy), followed by the kidneys (6 mGy), as well as the liver and the spleen (3 mGy each). CCK<jats:sub>2<\/jats:sub>R-expressing tumor manifestations could be detected in 2 of the 6 patients, including lymph node, bone, and liver metastases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n                                 <jats:sup>68<\/jats:sup>Ga-DOTA-CCK-66 exhibits a favorable dosimetry. Beyond physiologic receptor expression of the stomach, no other relevant tracer accumulation could be observed, rendering this organ at risk in case of subsequent radioligand therapy using <jats:sup>177<\/jats:sup>Lu-DOTA-CCK-66.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005355","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T15:50:38Z","timestamp":1722613838000},"page":"1091-1097","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Biodistribution and Radiation Dosimetry for 68Ga-DOTA-CCK-66, a Novel CCK2R-Targeting Compound for Imaging of Medullary Thyroid Cancer"],"prefix":"10.1097","volume":"49","author":[{"given":"Oliver","family":"Viering","sequence":"first","affiliation":[{"name":"Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Rinscheid","sequence":"additional","affiliation":[{"name":"Medical Physics and Radiation Protection, University Hospital Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Holzleitner","sequence":"additional","affiliation":[{"name":"TUM School of Natural Sciences, Department of Chemistry, Chair of Pharmaceutical Radiochemistry, Technical University of Munich, Garching, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Dierks","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Kircher","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgine","family":"Wienand","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Patt","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-J\u00fcrgen","family":"Wester","sequence":"additional","affiliation":[{"name":"TUM School of Natural Sciences, Department of Chemistry, Chair of Pharmaceutical Radiochemistry, Technical University of Munich, Garching, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph A.","family":"Bundschuh","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian H.","family":"Pfob","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"American Thyroid Association guidelines task force on medullary thyroid carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","year":"2015","journal-title":"Thyroid"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","year":"2023","journal-title":"N Engl J Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.beem.2017.04.009","article-title":"Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer","volume":"31","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"17588359221101691","DOI":"10.1177\/17588359221101691","article-title":"RET kinase inhibitors for RET-altered thyroid cancers","volume":"14","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1089\/thy.2018.0351","article-title":"F-18-Dopa positron emission tomography\/computed tomography is more sensitive than whole-body magnetic resonance imaging for the localization of persistent\/recurrent disease of medullary thyroid cancer patients","volume":"29","year":"2019","journal-title":"Thyroid"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1210\/jc.2007-1211","article-title":"Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels","volume":"92","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","article-title":"EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-017-3759-4","article-title":"Diagnostic utility of PET\/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib10-20250621","first-page":"1377","article-title":"Cholecystokinin(CCK)-a and CCK-B\/gastrin receptors in human tumors","volume":"57","year":"1997","journal-title":"Cancer Res"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/snuc.2002.31028","article-title":"Cholecystokinin-B\/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies","volume":"32","year":"2002","journal-title":"Semin Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s00259-022-05992-6","article-title":"[111In]in-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC phase I clinical trial","volume":"50","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.3390\/jcm9113507","article-title":"Advances in the management of medullary thyroid carcinoma: focus on peptide receptor radionuclide therapy","volume":"9","year":"2020","journal-title":"J Clin Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2967\/jnumed.119.233031","article-title":"Cholecystokinin 2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma: results of the Lumed phase 0a study","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2967\/jnumed.122.264977","article-title":"Preliminary clinical experience with cholecystokinin-2 receptor PET\/CT using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer","volume":"64","year":"2023","journal-title":"J Nucl Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2967\/jnumed.123.266537","article-title":"Preclinical evaluation of minigastrin analogs and proof-of-concept [68Ga]Ga-DOTA-CCK-66 PET\/CT in 2 patients with medullary thyroid cancer","volume":"65","year":"2024","journal-title":"J Nucl Med"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2967\/jnumed.123.266380","article-title":"CCK2 receptor-targeted PET\/CT in medullary thyroid cancer using [68Ga]Ga-DOTA-CCK-66","volume":"65","year":"2024","journal-title":"J Nucl Med"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40658-019-0253-z","article-title":"Multicentre quantitative 68Ga PET\/CT performance harmonisation","volume":"6","year":"2019","journal-title":"EJNMMI Phys"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2967\/jnumed.114.151647","article-title":"Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"102504","DOI":"10.1118\/1.4820367","article-title":"Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient","volume":"40","year":"2013","journal-title":"Med Phys"},{"key":"bib21-20250621","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","year":"2005","journal-title":"J Nucl Med"},{"issue":"4 Suppl","key":"bib22-20250621","first-page":"1093","article-title":"Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy","volume":"116","year":"2010","journal-title":"Cancer"},{"issue":"2\u20134","key":"bib23-20250621","first-page":"1","article-title":"The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103","volume":"37","year":"2007","journal-title":"Ann ICRP"},{"issue":"1\u20133","key":"bib24-20250621","first-page":"1","article-title":"1990 Recommendations of the International Commission on Radiological Protection","volume":"21","year":"1991","journal-title":"Ann ICRP"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2967\/jnumed.115.156133","article-title":"Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"issue":"1\u20132","key":"bib26-20250621","first-page":"1","article-title":"Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007","volume":"38","year":"2008","journal-title":"Ann ICRP"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2967\/jnumed.113.120600","article-title":"Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"VISION investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"ESMO guidelines committee. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","year":"2020","journal-title":"Ann Oncol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/j.1476-5381.2012.01878.x","article-title":"The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat","volume":"166","year":"2012","journal-title":"Br J Pharmacol"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib32-20250621","first-page":"L15","article-title":"The CCK-2 receptor agonist Lu-177-PP-F11N for PRRT of medullary thyroid cancer\u2014recent results of the phase 1 \u201cLUMED\u201d study","volume":"60","year":"2021","journal-title":"Nuklearmedizin"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:06:05Z","timestamp":1750532765000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005355","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,2]]}}}